GLAXF - GlaxoSmithKline plc

Other OTC - Other OTC Delayed price. Currency in USD
19.80
-0.04 (-0.20%)
At close: 3:53PM EDT
Stock chart is not supported by your current browser
Previous close19.84
Open20.17
Bid0.00 x 0
Ask0.00 x 0
Day's range19.80 - 20.17
52-week range18.14 - 21.30
Volume7,237
Avg. volume2,334
Market cap102.029B
Beta (3Y monthly)0.52
PE ratio (TTM)39.92
EPS (TTM)0.50
Earnings dateN/A
Forward dividend & yield0.97 (5.09%)
Ex-dividend date2019-05-16
1y target estN/A
Trade prices are not sourced from all markets
  • GSK pharma head flags need for speed in high-pressure drug market
    Reutersyesterday

    GSK pharma head flags need for speed in high-pressure drug market

    Doing things one at a time in drug development is not a luxury that GlaxoSmithKline can afford any longer, the head of pharmaceuticals at Britain's largest drugmaker told Reuters. Luke Miels, who joined GSK in September 2017 after a contract dispute with his former employer AstraZeneca, said picking the most promising projects and developing them quickly now takes precedence over spreading the risk of failure.

  • Reuters5 days ago

    GSK signs up gene-editing pioneers in drug discovery alliance

    GlaxoSmithKline, Britain's largest drugmaker, will pay up to $67 million (52.88 million pounds) over a five-year period for the new Laboratory for Genomics Research, which will be jointly run with the University of California and led by researchers such as Jennifer Doudna, a co-inventor of the CRISPR gene-editing technology. New gene editing tools - with CRISPR/Cas9 as the most prominent example - have thrown the door wide open for rearranging the genetic code much more precisely and at lower costs than previously possible. The technology made headlines last year when a Chinese scientist caused outrage with a claim to have "gene-edited" babies, but CRISPR/Cas9 can also be used in medical and agricultural research without interfering with the human germline.

  • Business Wire12 days ago

    Nucala (mepolizumab) Gains FDA Approval for Two New Self-Administration Options

    GlaxoSmithKline (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved two new methods for administering Nucala (mepolizumab), an autoinjector and a pre-filled safety syringe, for patients or caregivers to administer once every four weeks, after a healthcare professional decides it is appropriate. This is the first anti-IL5 biologic to be licensed in the US for at-home administration, and the first respiratory biologic to be approved for administration via an autoinjector. This approval will give healthcare professionals and people living with severe eosinophilic asthma (SEA) or the rare disease eosinophilic granulomatosis with polyangiitis (EGPA) the option for Nucala to be administered outside of a clinical setting by a patient or caregiver after their healthcare professional agrees this approach is appropriate.

  • Better Buy: GlaxoSmithKline vs. Merck
    Motley Fool12 days ago

    Better Buy: GlaxoSmithKline vs. Merck

    Which stock wins in a matchup between these two big drugmakers?

  • Handful of FTSE-100 chiefs to meet Trump during UK state visit
    Sky News18 days ago

    Handful of FTSE-100 chiefs to meet Trump during UK state visit

    The bosses of Barclays, GlaxoSmithKline (GSK) and National Grid are among a handful of British company executives ‎invited for talks with US President Donald Trump during his state visit to the UK next week. Sky News has exclusively obtained the list of companies that will be represented at a roundtable breakfast with Mr Trump and Theresa May, the outgoing prime minister, on Tuesday. The chairman of defence contractor BAE Systems‎ and chief executive of Cillit Bang-maker Reckitt Benckiser are understood to make up the contingent of British companies, while US counterparts will include executives from JP Morgan, the fund manager Fidelity, defence company Lockheed Martin, cosmetics giant Estee Lauder and Splunk Software Technology, City sources said on Friday.

  • Reuters26 days ago

    GSK brings back bonuses for some sales reps

    Loosening the reins on bonuses will "uphold our ethical and values-led approach to (healthcare professional) engagement, in full compliance with laws and policies, whilst supporting delivery of strong performance," GSK said in a statement on its website. In 2012, the British group scrapped performance-based payments in the U.S. to avoid a repeat of aggressive sales practices.

  • Reuters26 days ago

    GSK's shingles vaccine approved for use in China in adults aged 50 and above

    The company said the vaccine will be introduced in phases in China, starting in 2020, to ensure reliable supply to all countries, where it has been launched. Shingrix, which has already been approved for use in the European Union, the United States, Canada, Japan and Australia, brought in 357 million pounds in the latest quarter. The approval comes after China included the vaccine in a list of 48 "clinically urgently needed new medicines" designated for faster review.

  • GSK to change incentives for sales representatives
    Reuters26 days ago

    GSK to change incentives for sales representatives

    The company said the changes reflected the shift in GSK's portfolio towards innovative specialty care products, including oncology. GSK said it would make changes to its incentive program for pharmaceutical and vaccines sales representatives, to be applied initially in the United States, UK and Canada from July 2019. In specialty care, the capped variable pay element of a sales representative's salary will be evaluated on the basis of individual sales targets, it said.

  • Better Buy: Johnson & Johnson vs. GlaxoSmithKline
    Motley Fool26 days ago

    Better Buy: Johnson & Johnson vs. GlaxoSmithKline

    Which of these top dividend-paying pharma stocks is the better buy right now?

  • 3 Top Stocks With High Dividend Yields
    Motley Fool26 days ago

    3 Top Stocks With High Dividend Yields

    Looking for stocks that pay you back? Here are three you can add to your list today.

  • Reuterslast month

    GSK and Novartis liniment marketing misled Australian consumers - court

    The Australian subsidiaries of British drugmaker GlaxoSmithKline and Swiss drugmaker Novartis misled customers and broke the law by promoting identical liniments as though they could treat specific ills, an Australian court found on Friday. The court said the companies admitted marketing Voltaren Osteo Gel as a treatment for osteoarthritis-related pain when its ingredients were the same as a cheaper Voltaren product, Emulgel. Judge Robert Bromwich said in a written decision that it was part of a "deliberate and considered marketing strategy".

  • Reuterslast month

    GSK-Pfizer deal gets approval from Australia's anti-trust watchdog

    The two pharmaceutical giants in December said they would combine their consumer health businesses in a joint venture that would be 68 percent-owned by GSK. The Australian Competition and Consumer Commission (ACCC) said products produced and sold by GSK and Pfizer in Australia would face strong competition from other players. For example, GSK's well-known pain management product - Panadol - would face strong competition from Reckitt Benckiser's Nurofen.

  • Reuters - UK Focuslast month

    UK regulator investigates China's state broadcaster for airing TV confession

    Britain's broadcasting watchdog has launched a formal investigation into whether a confession made by a British man and aired on China's state broadcaster broke UK broadcasting rules when shown there. The investigation relates to a complaint made by Briton Peter Humphrey and his American wife Yu Yingzeng, who were both sentenced in China in 2014 for illegally obtaining private records of Chinese citizens and selling the information to clients including drugmaker GlaxoSmithKline. Humphrey says China Central Television, which broadcast the footage via its international subsidiary China Global Television Network (CGTN), may have breached UK fairness rules by distributing what he said was a forced confession which prejudiced a subsequent trial against him.

  • Comparing the EPS Growth Trajectories of PFE and GSK
    Market Realistlast month

    Comparing the EPS Growth Trajectories of PFE and GSK

    Pfizer or GlaxoSmithKline: Which Is a Better Pick in May?(Continued from Prior Part)EPS performanceOn its first-quarter earnings conference call, Pfizer (PFE) increased its 2019 adjusted diluted EPS guidance by $0.01 at the midpoint to

  • What Are Analysts Recommending for PFE and GSK in May?
    Market Realistlast month

    What Are Analysts Recommending for PFE and GSK in May?

    Pfizer or GlaxoSmithKline: Which Is a Better Pick in May?(Continued from Prior Part)Milestones achieved in MayOn May 6, Pfizer (PFE) issued a press release announcing the FDA’s approval of two oral formulations of tafamidis, Vyndaqel and Vyndamax,

  • Comparing the Relative Valuations of PFE and GSK
    Market Realistlast month

    Comparing the Relative Valuations of PFE and GSK

    Pfizer or GlaxoSmithKline: Which Is a Better Pick in May?First-quarter performancePfizer (PFE) and GlaxoSmithKline (GSK) reported their first-quarter earnings results on April 30 and May 1, respectively.In the first quarter, Pfizer surpassed

  • UK's Vectura wins patent infringement case against GlaxoSmithKline in U.S
    Reuterslast month

    UK's Vectura wins patent infringement case against GlaxoSmithKline in U.S

    A jury trial in a Delaware district court on Friday found that one of Vectura's U.S. patents was infringed by sales of three of GSK's Ellipta products in the United States, Vectura said. The jury found that GSK, which is also a UK-based pharmaceutical company, willfully infringed the patent, which Vectura said gives it the right to seek enhanced damages. Vectura expects to seek application of the 3 percent royalty to sales of the infringing products through the end of the patent term in mid-2021, it said.

  • Reuters - UK Focuslast month

    UK's Vectura wins patent infringement case against GlaxoSmithKline in U.S.

    British drugmaker Vectura Group Plc said on Saturday that it won a patent infringement litigation case against GlaxoSmithKline Plc in the United States and has been awarded $89.7 million in damages for the period from August 2016 through December 2018. A jury trial in a Delaware district court on Friday found that one of Vectura's U.S. patents was infringed by sales of three of GSK's Ellipta products in the United States, Vectura said. The jury found that GSK, which is also a UK-based pharmaceutical company, willfully infringed the patent, which Vectura said gives it the right to seek enhanced damages.

  • Reuters2 months ago

    UK Stocks-Factors to watch on May 3

    (Adds company news items and futures) May 3 (Reuters) - Britain's FTSE 100 index is seen opening 1 point higher at 7,352 on Friday, according to financial bookmakers, while FTSE 100 futures were up 0.13 ...

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes